The Utility of Collagen VII Topical Gene Therapy in Treatment of Surgical Defect after Excision of Recessive Dystrophic Epidermolysis Bullosa associated Squamous Cell Carcinoma

This case report describes the use of beremagene geperpavec (B-VEC), the first FDA-approved topical gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), in the treatment of a large surgical defect following excision of squamous cell carcinoma (SCC) in a 55-year-old RDEB patient. After a wide local excision, the wound was treated with B-VEC, resulting in complete healing within 7 weeks, with no complications or recurrence at 10-month follow-up. This novel approach highlights the potential of B-VEC to improve surgical outcomes and wound healing in RDEB patients.